

Supplementary material:

	Month 1 of BP (n= 8057)	Month 2 of BP (n= 4446)	Month 3 of BP (n= 9108)	Rest of Follow-up (n=209952)
AF (%)	19.4%	13.1%	10.9%	11.0%
A Flutter (%)	1.3%	1.4%	0.9%	1.2%
A Tachycardia (%)	0.1%	0.1%	0.1%	0.1%
Sinus Rhythm (%)	79.3%	85.4%	88.1%	87.7%

Table S1: Classification and prevalence of the different ECG patterns during and after the blanking period. the sample size reflects the number of ECG strips submitted during the specified period.

	No recurrence (N=362)	Recurrence of AA (N=326)	Total (N=688)	p-value
Conventional PVI	182 (50.3%)	166 (50.9%)	348 (50.6%)	0.87
PVI + Fibrosis-guided ablation	180 (49.7%)	160 (49.1%)	340 (49.4%)	

Table S2: Effect of the initial randomization of the DECAAF II trial

	AF After BP (N=130)	AF Within BP (N=287)	No AF (N=271)	Total (N=688)	p-value
Baseline Fibrosis Mean % (SD)	18.32 (7.65)	19.61 (7.46)	17.82 (7.05)	18.66 (7.37)	0.0121
Ablation Scar Mean % (SD)	9.28 (5.07)	9.41 (4.94)	10.35 (5.13)	9.75 (5.05)	0.0422

Table S3: Effect of baseline fibrosis and ablation scar on early recurrence of arrhythmia and late recurrence